Valaris Ltd 8-K

What Happened
Valaris Ltd (VAL) reported that it entered into a Business Combination Agreement with Transocean Ltd on February 9, 2026 under which Transocean will acquire all outstanding Valaris shares in exchange for 15.235 shares of Transocean per Valaris share. The companies submitted a joint notice to the Committee on Foreign Investment in the United States (CFIUS) on April 21, 2026; CFIUS accepted the notice May 14, 2026 and issued written CFIUS Approval on June 29, 2026. The parties filed HSR notifications on March 2, 2026 and, after a withdrawal and refiling by Transocean, received a Second Request from the DOJ on May 4, 2026; they have agreed not to certify substantial compliance with the Second Request before July 31, 2026 and not to close until 60 days after both certify substantial compliance (unless the DOJ ends the waiting period earlier). A joint preliminary proxy statement on Schedule 14A was filed May 19, 2026.

Key Details

• Exchange ratio: 15.235 Transocean shares for each Valaris share (Business Combination Agreement dated Feb 9, 2026).
• CFIUS milestone: joint notice filed Apr 21, 2026; acceptance May 14, 2026; CFIUS Approval received Jun 29, 2026.
• Antitrust review: HSR filings on Mar 2, 2026; DOJ Second Request received May 4, 2026; parties committed not to certify substantial compliance before Jul 31, 2026 and not to close until 60 days after both certify substantial compliance.
• Process/filings: Joint preliminary proxy (Schedule 14A) filed May 19, 2026; transaction to be effected by a Bermuda scheme of arrangement; securities to be issued are expected to rely on Section 3(a)(10) exemption (not registered under the U.S. Securities Act).

Why It Matters
This 8-K confirms a major strategic transaction that would make Transocean the owner of Valaris through a stock-for-stock combination if approved by regulators and shareholders. CFIUS approval is a key regulatory milestone achieved, but the DOJ’s Second Request extends the antitrust review and sets timing conditions that delay closing until further DOJ clearance and shareholder votes. Investors should note the transaction’s timeline remains contingent on remaining regulatory approvals, shareholder approvals, and other customary closing conditions; the filing also highlights standard forward‑looking risks and urges investors to read the joint proxy and additional SEC filings for full details.